Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Access Denied You don't have permission to access "http://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-announces-positive-end-phase-1-meeting-fda" on this server. Reference #18.6c64645f.1785348319.e62ab5e https://errors.edgesuite.net/18.6c64645f.1785348319.e62ab5e